<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): NOVEMBER 17, 2000
AVIGEN, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)
<TABLE>
<S> <C>
0-28272 13-3647113
(Commission File No.) (I.R.S. Employer Identification No.)
</TABLE>
1201 HARBOR BAY PARKWAY, SUITE 1000
ALAMEDA, CALIFORNIA 94502
(Address of principal executive offices and zip code)
(510) 748-7150
(Registrant's telephone number, including area code)
1.
<PAGE> 2
Item 5. Other Matters
On November 17, 2000, Avigen announced that it signed a Hemophilia B gene
therapy deal with Bayer. A copy of the press release is filed as Exhibit 99.1
hereto and is incorporated herein by reference.
Item 7. Exhibits
Exhibit 99.1. Press Release Dated November 17, 2000.
2.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
AVIGEN, INC.
DATE: November 27, 2000 By: /s/ Thomas J. Paulson
-------------------------------------
Thomas J. Paulson
Vice President, Finance and
Chief Financial Officer
3.
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<S> <C>
Exhibit 99.1. Press Release Dated November 17, 2000.
</TABLE>
4.
